Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024. Biosimilar Jiyoutai awaits approval in China. FDA tightens Mounjaro supply due to high demand.
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."
ARCA Biopharma and Oruka Therapeutics merge, focusing on novel biologics for chronic skin diseases like plaque psoriasis. ORKA-001 and ORKA-002 advance, supported by $275 million investment. Expect clinical trials in 2025. Merger closes Q3 2024. ABIO shares up 81.3% premarket."
Helius Medical partners with Lovell Govt Services to provide PoNS device to federal healthcare systems. PoNS, a short-term treatment for gait deficit in MS, shows promising real-world results. Seeking FDA authorization for stroke treatment. HSDT shares surge 38% in premarket trading.
FDA approves Vanda Pharmaceuticals' Fanapt tablets for bipolar I disorder manic or mixed episodes in adults. Fanapt, an atypical antipsychotic, shows significant improvement over placebo in pivotal study.
Facing delays, the FDA's proposal to ban menthol cigarettes in the US encounters setbacks as White House officials miss yet another deadline. Industry giants like Altria and British American Tobacco face uncertainty as calls to enforce the ban intensify.
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over future growth. Soriot's strategic overhaul focuses on R&D and acquisitions.
Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.